A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Der ernüchternde Kampf gegen die Killerkeime
Media - published on 23 Jan 2018

Der ernüchternde Kampf gegen die Killerkeime

Anja Ettel reports on the role of the pharmaceutical industry in the fight against resistant pathogens.

This article describes companies’ antimicrobial pipelines and the growing demand for new antibiotics following the publication of the Antimicrobial Resistance Benchmark.

„In der Konsequenz kann man heute mit alten Antibiotika nur wenig verdienen – und morgen mit der Entwicklung von neuen Antibiotika ebenfalls nur wenig Geld machen“, erklärt Iyer den Grund für das Marktversagen.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |